II期临床试验-话题@MedSci

#II期临床试验#

174篇内容 | 3268人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1931438, encodeId=4b9a193143821, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, objectType=article, longId=142862, objectId=f2bb142862d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2bb142862d6, replyNumber=0, likeNumber=88, createdTime=2019-04-20, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2bb142862d6, moduleTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2bb142862d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931434, encodeId=4f2b1931434c1, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Teva的皮下哮喘药物在III期临床试验中失败, objectType=article, longId=127488, objectId=74dd12e488a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74dd12e488a0, replyNumber=0, likeNumber=66, createdTime=2018-12-29, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74dd12e488a0, moduleTitle=Teva的皮下哮喘药物在III期临床试验中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74dd12e488a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931426, encodeId=3b25193142690, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, objectType=article, longId=124106, objectId=bed9124106d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed9124106d6, replyNumber=0, likeNumber=63, createdTime=2018-05-20, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed9124106d6, moduleTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed9124106d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931436, encodeId=b0501931436b9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, objectType=article, longId=135459, objectId=662a13545945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662a13545945, replyNumber=0, likeNumber=80, createdTime=2018-10-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662a13545945, moduleTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662a13545945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931425, encodeId=6e80193142511, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, objectType=article, longId=120485, objectId=e3de120485e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3de120485e7, replyNumber=0, likeNumber=80, createdTime=2018-04-15, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3de120485e7, moduleTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3de120485e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931431, encodeId=bfba193143112, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, objectType=article, longId=125185, objectId=de17125185b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de17125185b2, replyNumber=0, likeNumber=49, createdTime=2018-02-19, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de17125185b2, moduleTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de17125185b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931435, encodeId=0186193143527, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Mithra宣布Donesta的II期临床试验已经完成, objectType=article, longId=128113, objectId=70ca12811316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ca12811316, replyNumber=0, likeNumber=0, createdTime=2018-10-19, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ca12811316, moduleTitle=Mithra宣布Donesta的II期临床试验已经完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ca12811316)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931432, encodeId=3327193143254, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, objectType=article, longId=125219, objectId=0ec912521937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec912521937, replyNumber=0, likeNumber=0, createdTime=2018-12-16, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec912521937, moduleTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec912521937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, objectType=article, longId=124108, objectId=397812410839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397812410839, replyNumber=0, likeNumber=64, createdTime=2018-04-16, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397812410839, moduleTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397812410839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931429, encodeId=da14193142910, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, objectType=article, longId=124749, objectId=622e124e49ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622e124e49ed, replyNumber=0, likeNumber=73, createdTime=2018-05-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622e124e49ed, moduleTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622e124e49ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931424, encodeId=b3ec193142474, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, objectType=article, longId=85558, objectId=25048555835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25048555835, replyNumber=0, likeNumber=57, createdTime=2017-08-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25048555835, moduleTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25048555835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931423, encodeId=08291931423c4, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, objectType=article, longId=70373, objectId=0c80e0373e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c80e0373e2, replyNumber=0, likeNumber=79, createdTime=2016-12-02, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c80e0373e2, moduleTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c80e0373e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931421, encodeId=ce0d19314218b, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验, objectType=article, longId=56022, objectId=21385602249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21385602249, replyNumber=0, likeNumber=102, createdTime=2015-12-30, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21385602249, moduleTitle=招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21385602249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931419, encodeId=1da41931419dd, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, objectType=article, longId=56014, objectId=262d56014f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d56014f0, replyNumber=0, likeNumber=62, createdTime=2016-07-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d56014f0, moduleTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262d56014f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931420, encodeId=9abe1931420c6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, objectType=article, longId=56018, objectId=86745601843, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86745601843, replyNumber=0, likeNumber=48, createdTime=2015-11-06, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86745601843, moduleTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86745601843)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931418, encodeId=512219314187e, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验, objectType=article, longId=56011, objectId=342c560114a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=342c560114a, replyNumber=0, likeNumber=75, createdTime=2016-04-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=342c560114a, moduleTitle=招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=342c560114a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931417, encodeId=b94c193141e3f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段, objectType=article, longId=55622, objectId=6995556228c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6995556228c, replyNumber=0, likeNumber=116, createdTime=2015-12-01, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6995556228c, moduleTitle=第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6995556228c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931422, encodeId=0f3619314225c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验, objectType=article, longId=61125, objectId=30726112531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30726112531, replyNumber=0, likeNumber=70, createdTime=2016-07-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30726112531, moduleTitle=FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30726112531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931415, encodeId=d01d193141522, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想, objectType=article, longId=45906, objectId=c85f4590698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c85f4590698, replyNumber=0, likeNumber=68, createdTime=2015-02-17, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c85f4590698, moduleTitle=Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c85f4590698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931413, encodeId=5c0319314134d, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=汤森路透：五个进入III期临床试验的更具前景药物品种, objectType=article, longId=40850, objectId=966c408506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=966c408506a, replyNumber=0, likeNumber=55, createdTime=2014-11-01, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=966c408506a, moduleTitle=汤森路透：五个进入III期临床试验的更具前景药物品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=966c408506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床试验

2020-05-29

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据

2019-04-20

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

Teva的皮下哮喘药物在III期临床试验中失败

2018-12-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验

2018-05-20

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

PLOS ONE：天花疫苗MVA的III期临床试验结果

2018-10-18

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%

2018-04-15

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验

2018-02-19

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

Mithra宣布Donesta的II期临床试验已经完成

2018-10-19

zhouqu_8 (审核中...)

前往app查看评论内容

#II期临床试验#

EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验

2018-12-16

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验

2018-04-16

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验

2018-05-03

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点

2017-08-03

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）

2016-12-02

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验

2015-12-30

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验

2016-07-10

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验

2015-11-06

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验

2016-04-03

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段

2015-12-01

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验

2016-07-03

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想

2015-02-17

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

汤森路透：五个进入III期临床试验的更具前景药物品种

2014-11-01

科室
- - 订阅+
  - 更多科室
工具
服务